This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Losseff, N A Articles by Thompson, A J Search for Related Content PubMed PubMed Citation Articles by Losseff, N A Articles by Thompson, A J Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Autoimmune Diseases MRI Scans Multiple Sclerosis Social Bookmarking                         What's this?

The predictive value of gadolinium enhancement for long term disability in relapsing-remitting multiple sclerosis-preliminary results

NMR Research Unit, Institute of Neurology, Queen Square, London WC1N 3BG, UK

D H Miller

NMR Research Unit, Institute of Neurology, Queen Square, London WC1N 3BG, UK

D Kidd

NMR Research Unit, Institute of Neurology, Queen Square, London WC1N 3BG, UK

A J Thompson

NMR Research Unit, Institute of Neurology, Queen Square, London WC1N 3BG, UK

As short-term MRI studies are increasingly being used to monitor disease activity in multiple sclerosis (MS) it is vital to establish if short-term MRI activity is predictive of long term clinical outcome. We followed up after 5 years a group of 10 benign (relapsing-remitting MS with a disease duration 410 years and EDSS 43) and 10 early relapsing-remitting patients who previously had monthly serial MRI scans for 6 months. In the early relapsing-remitting group median EDSS at entry to the initial serial study was three and in the benign group 2.5. At 5-year follow up, five of these 20 patients had developed a definite deterioration in EDSS. The median number of new enhancing lesions detected originally in the group that had deteriorated was 11 (7-17) compared to 0 (0-5) new enhancing lesions, for those who had not deteriorated (P50.05). There was a trend towards a higher baseline T2 lesion load in the group with a definite change in EDSS but this was not significant. This study suggests that short-term measurement of the number of gadolinium enhancing lesions may predict long term outcome in relapsing-remitting MS.

Key Words: MS • enhancement • prediction • disability

Multiple Sclerosis, Vol. 7, No. 1, 23-25 (2001)
DOI: 10.1177/135245850100700105


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Daumer, A. Neuhaus, S. Morrissey, R. Hintzen, and G. C. Ebers MRI as an outcome in multiple sclerosis clinical trials Neurology, February 24, 2009; 72(8): 705 - 711. [Abstract] [Full Text] [PDF]

				W Rashid, G R Davies, D T Chard, C M Griffin, D R Altmann, A J Thompson, and D H Miller Relationship of triple dose contrast enhanced lesions with clinical measures and brain atrophy in early relapsing-remitting multiple sclerosis: a two-year longitudinal study Multiple Sclerosis, March 1, 2007; 13(2): 178 - 185. [Abstract] [PDF]

				F. Cotton, H. L. Weiner, F. A. Jolesz, and C. R.G. Guttmann MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals Neurology, February 25, 2003; 60(4): 640 - 646. [Abstract] [Full Text] [PDF]

				D. L. Arnold and P.M. Matthews MRI in the diagnosis and management of multiple sclerosis Neurology, April 23, 2002; 58(90084): S23 - 31. [Abstract] [Full Text]